Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Issues Abound Tracking Efficacy And Effectiveness In Clinical Trials

This article was originally published in Start Up

Executive Summary

A recent JAMA paper assesses the progress of ClinicalTrials.gov, concluding that concerns continue around the use of best methods for generating evidence and the capacity of the clinical trials enterprise to supply the high quality evidence needed to ensure confidence in guidelines. That these issues hold for interventional trials suggests that other strands of clinical research, notably those focused on comparative effectiveness, face similar if not even greater challenges to be able to provide meaningful real-world evidence.

You may also be interested in...



Califf’s Trial Design Prescription: Less Randomization, More Transparency

FDA’s new deputy commissioner is expected to advocate for innovation in clinical studies; Duke cardiologist has led numerous trials, including pivotal Xarelto study and Vytorin outcomes trial.

Develop CER Strategies, Or Be Left Behind, GSK Exec Says

Execs from GlaxoSmithKline and OptumInsight offer insight on the need for pharma companies to develop strategies that account for the growing role comparative effectiveness research is playing in reforming health care, a role that will continue despite what happens in legal and legislative circles in Washington, D.C.

Maintaining a Sustainable Environment for Innovation: Ending the Evidence Arms Race for Regulatory and Reimbursement Decision-Making

Increasing attention on containing healthcare costs has spurred new business opportunities in data aggregation, real-time analytics, and rapid translation of data into evidence on the value of new innovation. This has become a race for more and faster evidence. But is the investment made by manufacturers, payers, and the government resulting in better evidence to aid patients and clinicians in making better decisions?

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID1131511

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel